Conduit Pharmaceuticals Inc
NASDAQ:CDT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Conduit Pharmaceuticals Inc
Income from Continuing Operations
Conduit Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Conduit Pharmaceuticals Inc
NASDAQ:CDT
|
Income from Continuing Operations
-$39.2m
|
CAGR 3-Years
-100%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Income from Continuing Operations
$2.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Schlumberger NV
NYSE:SLB
|
Income from Continuing Operations
$3.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
Halliburton Co
NYSE:HAL
|
Income from Continuing Operations
$1.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Income from Continuing Operations
-$77.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Income from Continuing Operations
$529.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Conduit Pharmaceuticals Inc
Glance View
Conduit Pharmaceuticals Inc is a US-based company operating in industry. The company is headquartered in San Diego, California. The company went IPO on 2022-02-03. Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The firm is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. The company is used as a treatment option for Hashimoto’s Thyroiditis (HT) and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
See Also
What is Conduit Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
-39.2m
USD
Based on the financial report for Dec 31, 2025, Conduit Pharmaceuticals Inc's Income from Continuing Operations amounts to -39.2m USD.
What is Conduit Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-100%
Over the last year, the Income from Continuing Operations growth was -120%. The average annual Income from Continuing Operations growth rates for Conduit Pharmaceuticals Inc have been -100% over the past three years .
